Novo Nordisk expands Wegovy savings program

PLAINSBORO, N.J. - Novo Nordisk, a prominent player in the pharmaceutical industry with an impressive 85% gross profit margin according to InvestingPro data, has broadened its Wegovy® savings offer, now extending a reduced cost of $499 per month to all eligible cash-paying patients for various doses of the obesity treatment, Wegovy® (semaglutide) injection. The pharmaceutical company, which has demonstrated robust revenue growth of 25% over the last twelve months, announced today that the offer, which was previously exclusive to the NovoCare® Pharmacy, would now be available at retail pharmacies.

The updated savings program aims to make Wegovy® more accessible to individuals managing obesity, offering a 28-day supply at a lower price than the previous $650 per month. Patients with commercial insurance that does not cover obesity medicines can also benefit from this offer, while those with coverage may pay as little as $0, subject to a maximum savings of $225. This strategic pricing move comes as Novo Nordisk maintains its strong market position, with InvestingPro analysis showing an impressive return on assets of 25.89% and an overall financial health rating of GREAT.

Dave Moore, Executive Vice President of U.S. Operations and Global Business Development, and President of Novo Nordisk Inc., emphasized the company’s commitment to developing innovative medicines and making them accessible and affordable.

Wegovy® is an FDA-approved semaglutide injection prescribed alongside a reduced-calorie diet and increased physical activity to reduce cardiovascular risks in adults with obesity or overweight with weight-related medical issues. It is also prescribed to help adults and children aged 12 and over with obesity, or some adults with overweight who also have weight-related medical problems, to lose excess body weight and maintain weight loss.

The Wegovy® savings offer is not applicable to patients enrolled in government-funded healthcare programs. NovoCare® Pharmacy continues to support cash-paying Wegovy® patients with home delivery, benefit verification, refill reminders, and access to live support from case managers.

Novo Nordisk, with a century-long history in developing diabetes care medicines, now extends its expertise to tackle other chronic diseases such as obesity and rare blood and endocrine disorders. The company underscores the importance of using semaglutide-containing medicines responsibly, as they are not interchangeable and should be used strictly according to approved indications.

This expansion of the Wegovy® savings offer reflects Novo Nordisk’s ongoing efforts to ensure patient safety and access to their medications. The company’s strong financial position, including its 37-year track record of consistent dividend payments, supports these patient-centric initiatives. More information about the savings offer can be found at Wegovy.com, and further details about NovoCare® Pharmacy services are available at NovoCare.com. For comprehensive financial analysis and additional insights about Novo Nordisk’s market performance, visit InvestingPro, where subscribers can access over 10 more exclusive ProTips and detailed financial metrics.

The information in this article is based on a press release statement from Novo Nordisk.

In other recent news, Novo Nordisk Inc. has introduced NovoCare® Pharmacy, a service that offers home delivery of Wegovy® (semaglutide) at a reduced price of $499 per month for cash-paying patients. This initiative is primarily aimed at uninsured individuals and those lacking coverage for obesity medications, providing a more affordable and convenient option for accessing this FDA-approved weight management drug. The launch follows the FDA’s confirmation that the supply shortage of Wegovy® has been resolved, ensuring adequate availability to meet demand in the U.S. Additionally, NovoCare® Pharmacy, operated by CenterWell Pharmacy, offers benefit verification, refill reminders, and case manager support to enhance patient experience. This service aims to mitigate the risks associated with counterfeit or illegitimate compounded semaglutide products, ensuring patients receive genuine medication. Dave Moore, Executive Vice President of U.S. Operations and Global Business Development and President of Novo Nordisk Inc., emphasized the company’s commitment to improving medicine affordability and accessibility. Novo Nordisk plans to expand the savings offer for Wegovy® to cash-paying patients using traditional retail pharmacies in the future. The company continues to prioritize patient safety with proactive measures and encourages healthcare professionals and patients to access further information on semaglutide.com.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.